Rugiet Ready vs BlueChew Gold vs MEDVi QUAD: Which Combination ED Treatment Is Best?

Three products now compete in the multi-ingredient sublingual ED space. Each combines multiple active ingredients into a single dose, but the formulas, formats, and pricing differ significantly — and MEDVi QUAD changed its formula in July 2026. Here is our honest, research-based breakdown to help you decide.

Ingredients: The Core Difference

All three products share the same two-drug foundation: sildenafil (Viagra) and tadalafil (Cialis), the two most widely prescribed PDE5 inhibitors. Everything past that is where they diverge — and as of July 2026, they diverge further than they used to.

Rugiet Ready is a 3-in-1 formula: sildenafil, tadalafil, and apomorphine (a dopamine agonist aimed at the mental-arousal side). This is the original multi-ingredient sublingual formula that created the category in 2020.

BlueChew Gold is a 4-in-1: sildenafil, tadalafil, apomorphine, and oxytocin — a neuropeptide associated with emotional bonding and social behavior. BlueChew markets this as supporting "emotional connection" and "deeper intimacy."

MEDVi QUAD changed on July 16, 2026. It dropped vardenafil and apomorphine and added two different ingredients:

L-citrulline — an amino acid that converts to L-arginine in the body, raising nitric-oxide production and supporting blood-vessel dilation. That is the same pathway PDE5 inhibitors depend on, approached from the other end. A small single-blind study (Cormio et al., Urology, 2011, 24 men) found oral L-citrulline improved erection hardness in men with mild ED — 50% of men improved versus 8% on placebo. It is a supplement-grade amino acid, not an FDA-approved ED drug. Call it what it is: a nitric-oxide amplifier with early but genuine clinical evidence in mild ED.

PT-141 (bremelanotide) — a melanocortin (MC4R) agonist that acts on the brain's desire and arousal centers rather than on blood flow. It is FDA-approved as Vyleesi (2019) for low sexual desire (HSDD) in premenopausal women, by injection. In men, early-phase trials of intranasal bremelanotide showed erectogenic effects, including in some sildenafil non-responders, but it was never approved for ED — development stopped partly over blood-pressure concerns. Its use in QUAD is compounded, off-label, and prescriber-supervised.

One factual consequence of the reformulation: QUAD is now the only one of these three without apomorphine. Rugiet Ready and BlueChew Gold both still contain it. Apomorphine is a dopamine agonist also used in Parkinson's disease, and it drew media scrutiny in 2026.

Dosing note: QUAD is a compounded prescription. Per-ingredient amounts are set by the prescribing physician, not published as a fixed retail strength, so we do not quote mg figures for it.

Desire Ingredients: Oxytocin vs PT-141

Both BlueChew Gold and the new QUAD go after the same thing beyond blood flow: desire. They do it with very different ingredients, and the evidence behind them is not comparable. BlueChew Gold's marketing positions oxytocin as a meaningful addition. The published science tells a different story.

Problem 1: No ED evidence. Oxytocin has never been approved for, or clinically validated as, an erectile dysfunction treatment. While some early-stage research suggests oxytocin may play a role in sexual behavior, no randomized controlled trials have demonstrated that it improves erection quality, firmness, or reliability.

Problem 2: Near-zero sublingual absorption. Published research shows sublingual oxytocin has approximately 4.5% bioavailability with "10-fold variation" between individuals. The same research concluded that sublingual delivery "would not seem a reliable route" for administering oxytocin therapeutically. Even intranasal delivery — the more common method in research settings — achieves only 11% bioavailability.

This means that even if oxytocin were proven effective for ED (which it is not), the sublingual tablet format used by BlueChew Gold would deliver therapeutically insignificant amounts to most users.

By contrast, QUAD's desire ingredient is PT-141 (bremelanotide), and the evidence base is not in the same category. PT-141 has completed human clinical trials, and it holds an actual FDA approval — as Vyleesi, for low sexual desire in premenopausal women. Its ED use in men is off-label and unapproved, and early-phase male trials are the extent of the erectogenic data, so this is not a settled question either. But "human trial data plus an FDA approval in another indication" and "no randomized trials, 4.5% absorption" are very different starting points.

QUAD's other addition, L-citrulline, works on blood flow rather than desire: it raises nitric oxide, the same pathway sildenafil and tadalafil act on downstream. The clinical evidence is one small 24-man study in mild ED, which is real but thin. We would not call it a substitute for a PDE5 inhibitor, and neither does MEDVi — it sits alongside two of them.

Format and Delivery

All three products use sublingual delivery — placed under the tongue rather than swallowed — for faster absorption that bypasses the digestive system. But the physical formats differ.

Rugiet Ready: Sublingual troche (lozenge). Dissolves under the tongue in 5–10 minutes. The main drawback is temperature sensitivity — Rugiet asks you to store the troches in a cool, dry place at room temperature (74°F/23°C) or below, and above that they can soften or melt. Refrigeration is the fix rather than the rule: if a dose melts in transit and the blister pack is intact, Rugiet's guidance is to refrigerate it until it firms up and then take it normally. Rugiet also states that melting or freezing does not alter the active ingredients — heat affects the tablet's texture and handling — so this is the most frequently cited practical complaint in user reviews, but a handling one rather than a potency one.

BlueChew Gold: Rapidly dissolving tablet (RDT). Dissolves very quickly when placed under the tongue. More practical than Rugiet's troches for portability, as tablets are individually wrapped and less temperature-sensitive. However, the rapid dissolution may limit sublingual absorption time compared to slower-dissolving formats.

MEDVi QUAD: Sublingual liquid. A measured liquid dose placed under the tongue. No dissolution required — ingredients are already in solution. This provides the most consistent absorption and the fastest onset. No temperature sensitivity issues. Easy to carry.

Pricing Breakdown

Cheapest overall: BlueChew Gold wins on absolute price. If budget is your primary concern and you are comfortable with the oxytocin question, BlueChew Gold offers the lowest entry point.

Hardest to compare: Rugiet Ready. It publishes a starting per-dose price of $7.29 for its lowest strength and no monthly figure at all, with the price rising according to strength, pack count and delivery option. That entry price is close to BlueChew Gold's, but until you have completed the consultation and chosen a configuration there is no way to know what a month of Rugiet will actually cost you.

What $119 buys at QUAD: two FDA-approved PDE5 inhibitors plus two ingredients — L-citrulline and PT-141 — that are not approved for ED but do have published human data behind them. Whether that is worth $52 a month over BlueChew Gold depends entirely on how much weight you give PT-141's desire mechanism. If you only want blood-flow coverage, you are paying for ingredients you do not need.

Side Effects Compared

All three products share a common core side effect profile because all three contain sildenafil and tadalafil. Common effects include nasal congestion, mild headache, facial flushing, and dizziness. Serious effects are rare but include dangerously low blood pressure when combined with nitrate medications.

Rugiet Ready and BlueChew Gold both contain apomorphine, so nausea is a possibility with either — it is the effect most associated with that ingredient. QUAD no longer contains apomorphine after the July 2026 reformulation, so that particular route to nausea is gone from its profile.

QUAD's newer ingredients bring their own considerations. L-citrulline is a well-tolerated amino acid supplement. PT-141 is the one to raise with a prescriber: blood-pressure concerns were part of why its development for ED in men was stopped, and its use here is off-label and prescriber-supervised. Because QUAD is compounded, the amount of each ingredient is set by the prescribing physician rather than fixed at a retail strength.

BlueChew Gold's oxytocin, at the minimal amounts that absorb sublingually, is unlikely to contribute meaningful additional side effects.

User Reviews and Track Record

Rugiet Ready has by far the longest track record, with 1,594 Trustpilot reviews averaging 4.3 out of 5 (July 2026). Most positive reviews cite speed of onset, erection quality, and the dual-mechanism approach. Most negative reviews cite soft or melted troches, difficulty canceling subscriptions, and limited effectiveness for some users with severe ED.

BlueChew Gold is brand new (launched early 2026), but BlueChew as a company has served over 4 million men with its single-ingredient chewables. The brand has strong recognition, though Gold-specific reviews are still limited.

MEDVi QUAD is the newest entrant and independent reviews are sparse. The July 2026 reformulation makes this worse, not better: any user feedback published before mid-July describes the old sildenafil/tadalafil/vardenafil/apomorphine formula, not the one being sold now. Treat pre-July QUAD reviews as commentary on a discontinued product. This is the clearest risk in choosing QUAD today — you are buying on ingredient rationale, not on accumulated user validation.

Who Should Choose Which?

Frequently Asked Questions

Our Verdict

Each product has a clear strength. Rugiet Ready has the strongest track record. BlueChew Gold has the lowest price. MEDVi QUAD, after its July 2026 reformulation, is the only one of the three that pairs its PDE5 inhibitors with a desire ingredient backed by human trials.

The reformulation changes our reasoning, so we will be plain about it. The old case for QUAD was breadth of approved drugs — three PDE5 inhibitors, four ingredients with ED evidence. That case no longer applies. The new case is narrower and more specific: two proven PDE5 inhibitors, plus L-citrulline working the nitric-oxide pathway from the supply side, plus PT-141 addressing desire centrally. Every ingredient has published human clinical evidence for sexual function. Two of them are not FDA-approved for ED, and we are not going to pretend otherwise.

If your problem is partly desire rather than purely mechanical, that combination is the most interesting of the three, and QUAD is also the only one of the three without apomorphine. If your problem is purely blood flow, you are paying $119 for two drugs you can get more cheaply elsewhere.

If you are new to combination ED treatments and want the reassurance of a deeply established product with years of user feedback, Rugiet Ready remains the reasonable starting point. And if budget is the primary constraint, BlueChew Gold delivers the same two-drug core at the lowest cost — just do not pay a premium for the oxytocin.

Individual Reviews & Head-to-Heads